Expesicor, Inc.

This technology is applicable to both personalized pain treatment and the development of novel pain management therapies, such as non-opioid medications. MISSOULA, MT, November 7, 2019 -- Expesicor , a privately held, Montana-based company focused on preventing, treating, and curing neurological disorders, announced its participation in the National Institutes of Health’s (NIH) Helping to End Addiction Long-term Initiative or NIH HEAL Initiative. The Initiative takes an “all hands on deck” approach “to improve prevention and treatment strategies for opioid misuse and addiction and to enhance pain management.” Expesicor has been awarded $407,654 over one year for a grant that allows the company to further develop a novel positron emission tomography (PET) imaging agent, called EXP-1801, that enables the visualization and objective measurement of pain. This technology is applicable to both personalized pain treatment and the development of novel pain management therapies, such as non-opioid medications. “We’re honored to be part of the HEAL initiative,” said Dr. Braxton Norwood, Principal Investigator and CEO of Expesicor. “Safe and effective therapies for pain management are lacking and misuse is far too common. We’re confident that EXP-1801 will help improve pain treatment and contribute to the development of novel therapies with lower abuse potential.” As a clinical-stage company, Expesicor’s pipeline includes projects ranging from preclinical to Phase II clinical trials. In addition to imaging agents, the company’s assets include novel therapeutics and drug screening tools for neurological maladies including epilepsy, traumatic brain injury, and neurodegenerative disorders. “This project closely aligns with Expesicor’s mission to prevent, treat, and cure neurological disorders. EXP-1801 has broad potential to positively impact those living with pain-related disorders,” said David Booth, COO of Expesicor. “EXP-1801 could become the first tool that enables healthcare providers to objectively measure pain.” Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number R43NS115294. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. ### About Expesicor Expesicor is a clinical stage, privately-held, Montana-based company focused on preventing, treating, and curing neurological disorders. For more information, visit expesicor.com . About the HEAL initiative The National Institutes of Health launched the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, in April 2018 to improve prevention and treatment strategies for opioid misuse and addiction and enhance pain management. The NIH HEAL Initiative aims to improve treatments for chronic pain, curb the rates of opioid use disorder, and overdose and achieve long-term recovery from opioid addiction. To learn more, visit heal.nih.gov . Forward-Looking Statement This news release of Expesicor Inc, Kalispell, MT, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Contact: Expesicor Inc Box 10205 350 N Meridian Rd Kalispell, MT 59901 press@expesicor.com

Expesicor announced an official collaboration agreement with Novoron Bioscience, a private, San Diego-based biotechnology company developing novel therapeutic approaches to address disorders of the central nervous system. KALISPELL, MT, April 24, 2019 -- Expesicor , a privately held, Montana-based company focused on preventing, treating, and curing neurological disorders, today announced an official collaboration agreement with Novoron Bioscience , a private, San Diego-based biotechnology company developing novel therapeutic approaches to address disorders of the central nervous system. The two companies began exploratory work together in 2018 and have since co-developed a novel compound for the treatment of neurodegenerative disorders, like Alzheimer’s disease. The compound is currently in preclinical testing. Expesicor has extensive experience in drug development for neurological disorders, ranging from preclinical to Phase II clinical trials. The company’s development pipeline includes proprietary therapeutics, imaging probes, and drug screening tools for epilepsy, neurodegenerative disorders, depression, autism, and other brain disorders. “Our collaboration with Novoron is both very promising and productive,” said Expesicor CEO Braxton Norwood, PhD. “We believe that the unique compounds, which we’re co-developing with Novoron, can substantially slow the progression of degenerative conditions like Alzheimer’s and even reverse certain types of neuronal injury.” Novoron has developed a novel approach to restoring the regenerative capacity of the brain and spinal cord. Currently, they are advancing their pipeline of biologic therapeutics for the treatment of multiple sclerosis and spinal cord injury, in addition to ongoing work with Expesicor. “Our partnership with Expesicor has allowed us to extend our focus beyond multiple sclerosis and spinal cord injury into epilepsy, Alzheimer’s disease, and ALS,” said Novoron CEO Travis Stiles, PhD. “It has made it possible for us to move our co-developed compounds into preclinical trials, which gets us one step closer to being able to use them to treat diseases.” ### About Expesicor Expesicor is a privately-held, Montana-based company focused on preventing, treating, and curing neurological disorders. Expesicor’s development pipeline includes proprietary therapeutics, imaging probes, and drug screening tools for epilepsy, neurodegenerative disorders, depression, and other brain disorders. For more information, visit expesicor.com . About Novoron Bioscience Novoron Bioscience is a private biotech company developing novel therapeutic approaches to address disorders of the central nervous system. The company has made proprietary scientific discoveries to treat various pathologies of the central nervous system and is advancing a pipeline of biologic therapeutics for multiple sclerosis and spinal cord injury. Novoron is headquartered in San Diego and is part of the JLABS innovation community. For more information, visit novoron.com . Forward-Looking Statement This news release of Expesicor Inc, Kalispell, MT, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Contact: Expesicor Inc PO Box 10205 350 N Meridian Rd Kalispell, MT 59901 Press: press@expesicor.com